StreetInsider.com News Articles

Form 4 Amylyx Pharmaceuticals, For: May 21 Filed by: Firestone Karen

Tue, 26 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260526/26549620.html

Form 4 Amylyx Pharmaceuticals, For: May 21 Filed by: Firestone Karen

Tue, 26 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260526/26549620.html

Form SCHEDULE 13G/A Amylyx Pharmaceuticals, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504588.html

Form SCHEDULE 13G/A Amylyx Pharmaceuticals, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504588.html

Amylyx publishes phase 2 trial data for Wolfram syndrome treatment

Fri, 15 May 2026 12:12:19 -0400

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have been published in The Journal of Clinical Investigation.

The peer-reviewed publication reports Week 24 and Week 48 data from the open-label trial of AMX0035, an oral combination of sodium phenylbutyrate and taurursodiol, in 12 adults with Wolfram syndrome. The study showed improvements in pancreatic beta cell function through Week 48, as measured by C-peptide response to a mixed-meal tolerance test.

Secondary measures including HbA1c and time in target glucose range demonstrated improvement from baseline at both time points. Best-corrected visual acuity showed

Amylyx publishes phase 2 trial data for Wolfram syndrome treatment

Fri, 15 May 2026 12:12:19 -0400

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have been published in The Journal of Clinical Investigation.

Secondary measures including HbA1c and time in target glucose range demonstrated improvement from baseline at both time points. Best-corrected visual acuity showed

Amylyx publishes phase 2 trial data for Wolfram syndrome treatment

Fri, 15 May 2026 12:12:19 -0400

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have been published in The Journal of Clinical Investigation.

Secondary measures including HbA1c and time in target glucose range demonstrated improvement from baseline at both time points. Best-corrected visual acuity showed

Amylyx publishes phase 2 trial data for Wolfram syndrome treatment

Fri, 15 May 2026 12:12:19 -0400

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have been published in The Journal of Clinical Investigation.

Secondary measures including HbA1c and time in target glucose range demonstrated improvement from baseline at both time points. Best-corrected visual acuity showed

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Fri, 15 May 2026 12:11:00 -0400

Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic beta cell function, glycemic control, vision, and overall symptom burden
AMX0035 was generally well-tolerated, consistent with previously presented safety data
The Company continues to work with the FDA on a Phase 3 trial in Wolfram syndrome